Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1194
Abstract: The purpose of this study was to assess the effect of pevonedistat, a neural precursor cell expressed, developmentally down‐regulated protein 8 (NEDD8)‐activating enzyme inhibitor, on the heart rate‐corrected QT (QTc) interval in cancer patients. Patients… read more here.
Keywords: nedd8 activating; activating enzyme; effect pevonedistat; qtc ... See more keywords
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Science"
DOI: 10.1111/cas.14209
Abstract: The ubiquitin proteasome pathway is essential for the proliferation and survival of multiple myeloma (MM) cells. TAS4464, a novel highly potent inhibitor of NEDD8 activating enzyme, selectively inactivates cullin‐RING ubiquitin E3 ligases, resulting in accumulation… read more here.
Keywords: tas4464 novel; inhibitor; multiple myeloma; nedd8 activating ... See more keywords
The Nedd8‐activating enzyme inhibitor MLN4924 (TAK‐924/Pevonedistat) induces apoptosis via c‐Myc‐Noxa axis in head and neck squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Cell Proliferation"
DOI: 10.1111/cpr.12536
Abstract: The present study aimed to reveal expression status of the neddylation enzymes in HNSCC and to elucidate the anticancer efficacy and the underlying mechanisms of inhibiting neddylation pathway. read more here.
Keywords: inhibitor mln4924; enzyme inhibitor; tak 924; nedd8 activating ... See more keywords
Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.15050
Abstract: While death receptor ligands (Fas and TRAIL) kill chemoresistant tumor cell lines, related therapies have limited clinical efficacy as single agents. Death receptor signaling is modulated by nuclear factor-κB (NFκB), a family of transcription factors… read more here.
Keywords: death; death receptor; nedd8 activating; activating enzyme ... See more keywords